Search Results - "Seipp, C"

International planning of organization for medical care. From Health Care for the Community: Selected Papers of Dr. John B. Grant, 1963 by Seipp, C

Get full text

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens by ROSENBERG, S. A, YIFAN ZHAI, ROBERTS, B, WHITE, D. E, YANG, J. C, SCHWARTZENTRUBER, D. J, HWU, P, MARINCOLA, F. M, TOPALIAN, S. L, RESTIFO, N. P, SEIPP, C. A, EINHORN, J. H

“…The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the…”
Get full text

International Planning of Organization for Medical Care by Seipp, C

“…The two largest items of expense are the provision of a small "mixed" hospital with at least two physicians and other required hospital workers together with…”
Get full text

Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b by ROSENBERG, S. A, YANG, J. C, SCHWARTZENTRUBER, D. J, HWU, P, MARINCOLA, F. M, TOPALIAN, S. L, SEIPP, C. A, EINHORN, J. H, WHITE, D. E, STEINBERG, S. M

“…The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment…”
Get full text

Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions by Johnston, C., Seipp, C., Hommersen, P., Hoza, B., Fine, S.

“…Background  Despite their potential to influence treatment decisions, parents’ beliefs and attitudes regarding attention deficit hyperactivity disorder (ADHD)…”
Get full text

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2 by Rosenberg, Steven A, Yang, James C, Topalian, Suzanne L, Schwartzentruber, Douglas J, Weber, Jeffrey S, Parkinson, David R, Seipp, Claudia A, Einhorn, Jan H, White, Donald E

“…Objective.—To determine the efficacy of treatment using high-dose bolus Interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer.Design…”
Get full text

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 by Rosenberg, S A, Yannelli, J R, Yang, J C, Topalian, S L, Schwartzentruber, D J, Weber, J S, Parkinson, D R, Seipp, C A, Einhorn, J H, White, D E

“…Studies of human tumor-infiltrating lymphocytes (TILs) derived from patients with a variety of histologic types of cancer have demonstrated that cellular…”
Get more information

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer by Rosenberg, S A, Lotze, M T, Yang, J C, Topalian, S L, Chang, A E, Schwartzentruber, D J, Aebersold, P, Leitman, S, Linehan, W M, Seipp, C A

“…Treatment using interleukin-2 (IL-2) alone or in conjunction with lymphokine-activated killer (LAK) cells has been shown to mediate disease regression in…”
Get more information

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma by Rosenberg, Steven A, Yang, James C, Schwartzentruber, Douglas J, Hwu, Patrick, Marincola, Francesco M, Topalian, Suzanne L, Restifo, Nicholas P, Dudley, Mark E, Schwarz, Susan L, Spiess, Paul J, Parkhurst, Maria R, Kawakami, Yutaka, Seipp, Claudia A, Einhorn, Jan H, White, Donald E

“…The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant…”
Get full text

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients by Rosenberg, S A, Lotze, M T, Yang, J C, Aebersold, P M, Linehan, W M, Seipp, C A, White, D E

“…We have administered 1039 courses of high-dose interleukin-2 (IL-2) to 652 cancer patients. Five hundred ninety-six patients had metastatic cancer that either…”
Get full text

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer by Rosenberg, S A, Lotze, M T, Yang, J C, Linehan, W M, Seipp, C, Calabro, S, Karp, S E, Sherry, R M, Steinberg, S, White, D E

“…We performed an escalating dose study of the combined administration of interleukin-2 (IL-2) and alpha-interferon (alpha-IFN) in 94 patients with metastatic…”
Get more information

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells by Denicoff, K D, Rubinow, D R, Papa, M Z, Simpson, C, Seipp, C A, Lotze, M T, Chang, A E, Rosenstein, D, Rosenberg, S A

“…To study the neuropsychiatric manifestations of therapy with interleukin-2 and lymphokine-activated killer cells. Longitudinal survey of consecutive patients…”
Get more information

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study by Topalian, S L, Solomon, D, Avis, F P, Chang, A E, Freerksen, D L, Linehan, W M, Lotze, M T, Robertson, C N, Seipp, C A, Simon, P

“…Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with…”
Get more information

Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine by Rosenberg, Steven A, Yang, James C, Schwartzentruber, Douglas J, Hwu, Patrick, Marincola, Francesco M, Topalian, Suzanne L, Restifo, Nicholas P, Sznol, Mario, Schwarz, Susan L, Spiess, Paul J, Wunderlich, John R, Seipp, Claudia A, Einhorn, Jan H, Rogers-Freezer, Linda, White, Donald E

“…Patients with metastatic melanoma were immunized with an immunodominant peptide derived from the gp100 melanoma-melanocyte differentiation Ag that was modified…”
Get full text

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2 by Lotze, MT, Matory, YL, Ettinghausen, SE, Rayner, AA, Sharrow, SO, Seipp, CA, Custer, MC, Rosenberg, SA

“…Purified recombinant human interleukin 2 (RIL 2) derived from E. coli containing the inserted gene encoding for IL 2 was administered to 20 patients with a…”
Get full text

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings by Lotze, Michael T, Chang, Alfred E, Seipp, Claudia A, Simpson, Colleen, Vetto, John T, Rosenberg, Steven A

“…Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders…”
Get full text

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2 by Yang, J C, Topalian, S L, Schwartzentruber, D J, Parkinson, D R, Marincola, F M, Weber, J S, Seipp, C A, White, D E, Rosenberg, S A

“…Conjugation of polyethylene glycol to recombinant human interleukin-2 (IL-2) results in a compound, polyethylene glycol-modified IL-2 (PEG-IL-2) that retains…”
Get more information

Clinical effects and toxicity of interleukin-2 in patients with cancer by Lotze, M T, Matory, Y L, Rayner, A A, Ettinghausen, S E, Vetto, J T, Seipp, C A, Rosenberg, S A

“…Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have…”
Get more information

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report by Rosenberg, S A, Packard, B S, Aebersold, P M, Solomon, D, Topalian, S L, Toy, S T, Simon, P, Lotze, M T, Yang, J C, Seipp, C A

“…Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not…”
Get more information

Patterns of recurrence in patients with high-grade soft-tissue sarcomas by Potter, D A, Glenn, J, Kinsella, T, Glatstein, E, Lack, E E, Restrepo, C, White, D E, Seipp, C A, Wesley, R, Rosenberg, S A

“…From July 1975 to December 1982, 563 patients were referred to the Surgery Branch of the National Cancer Institute with the diagnosis of soft-tissue sarcoma…”
Get more information